DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Lynn Kramer - 1 Leqembi - 1 Eisai - 1 Kramer - 1
Top related locs:
Abington Abington , PA U.S Philadelphia
Top related orgs:
FDA - 1 Abington Neurological Associates - 1 Biogen - 1 CNBC - 1 Alzheimer's Association International Conference - 1 Alzheimer's Association - 1

Search resuls for: "Lynn Kramer"


2 mentions found


☆ Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
  + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
The newly FDA approved Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai. The study results on Leqembi, which Eisai shares with Biogen , also found that a patient's Alzheimer's disease worsens after they stop treatment. The results are a first glimpse at what Alzheimer's patients' future could look like on therapies such as Leqembi, which is currently taken twice a month through an infusion. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S.
Persons: Lynn Kramer, Leqembi, Eisai, Kramer Organizations: FDA, Abington Neurological Associates, Biogen, CNBC, Alzheimer's Association International Conference, Alzheimer's Association Locations: Abington, Abington , PA, U.S, Philadelphia
☆ Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
  + stars: | 2022-11-29 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +11 min
It involved 1,795 adults, ages 50 to 90, with mild cognitive impairment due to early Alzheimer’s disease or mild Alzheimer’s disease-related dementia. Such a score is consistent with early Alzheimer’s disease, with a higher number associated with more cognitive impairment. By 18 months, the CDR-SB score went up 1.21 points in the lecanemab group, compared with 1.66 in the placebo group. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group. The researchers also wrote that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths documented in the lecanemab group and seven in the placebo group.
0 next >>
Total: 2